Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|January 6, 2016
Optimizing Relationships Among Manufacturers and Providers
Author(s)Davy James, Managing Editor
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses methods to improve communication among drug manufacturers and health care providers.
Advertisement
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses methods to improve communication among drug manufacturers and health care providers.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5